Police & Firemen s Retirement System of New Jersey Buys 1,006 Shares of United Therapeutics Corporation $UTHR

Police & Firemen s Retirement System of New Jersey raised its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 6.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,833 shares of the biotechnology company’s stock after purchasing an additional 1,006 shares during the period. Police & Firemen s Retirement System of New Jersey’s holdings in United Therapeutics were worth $4,837,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. denkapparat Operations GmbH increased its position in United Therapeutics by 49.9% in the 2nd quarter. denkapparat Operations GmbH now owns 2,600 shares of the biotechnology company’s stock valued at $747,000 after buying an additional 866 shares in the last quarter. Weil Company Inc. grew its stake in United Therapeutics by 13.8% in the second quarter. Weil Company Inc. now owns 5,201 shares of the biotechnology company’s stock valued at $1,495,000 after acquiring an additional 631 shares during the period. Allworth Financial LP grew its stake in United Therapeutics by 147.2% in the second quarter. Allworth Financial LP now owns 356 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 212 shares during the period. Illinois Municipal Retirement Fund increased its holdings in shares of United Therapeutics by 26.9% during the second quarter. Illinois Municipal Retirement Fund now owns 20,614 shares of the biotechnology company’s stock valued at $5,923,000 after acquiring an additional 4,376 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in shares of United Therapeutics by 15.0% during the second quarter. Acadian Asset Management LLC now owns 206,018 shares of the biotechnology company’s stock worth $59,173,000 after purchasing an additional 26,813 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Up 0.9%

Shares of NASDAQ UTHR opened at $466.40 on Friday. The company has a market capitalization of $20.08 billion, a PE ratio of 17.67, a PEG ratio of 4.96 and a beta of 0.77. The stock’s 50 day moving average price is $432.38 and its 200-day moving average price is $349.68. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $479.50.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same period last year, the company posted $6.39 earnings per share. United Therapeutics’s quarterly revenue was up 6.8% compared to the same quarter last year. As a group, research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on UTHR. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Weiss Ratings reiterated a “buy (b-)” rating on shares of United Therapeutics in a report on Thursday. Cantor Fitzgerald upped their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. Oppenheimer raised their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Finally, HC Wainwright boosted their price objective on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $503.90.

Insiders Place Their Bets

In related news, EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $464.76, for a total value of $5,112,360.00. Following the transaction, the executive vice president directly owned 36,781 shares of the company’s stock, valued at approximately $17,094,337.56. The trade was a 23.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 4,000 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $460.00, for a total transaction of $1,840,000.00. Following the transaction, the chief executive officer owned 130 shares of the company’s stock, valued at approximately $59,800. The trade was a 96.85% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 471,435 shares of company stock valued at $200,294,552. 10.30% of the stock is currently owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.